Therapeutic options in relapsed or refractory peripheral T-cell lymphoma

Peripheral T-cell lymphoma (PTCL) represents a relatively rare group of heterogeneous non-Hodgkin lymphomas with a very poor prognosis.Current therapies, based on historical regimens for aggressive B-cell lymphomas, have resulted in insufficient patient outcomes.The majority of patients relapse rapidly, and current 5-year overall survival rates are only 10-30%.It is evident that new approaches to treat patients with PTCL are required.In recent years, prospective studies in PTCL have been initiated, mainly in patients with relapsed/refractory disease.In some of these, selected histologic subtypes have been evaluated in detail.As a consequence, numerous new therapies have been developed and shown activity in PTCL, including: agents targeting the immune system (e.g.brentuximab vedotin, alemtuzumab, lenalidomide); histone deacetylase inhibitors (romidepsin, belinostat); antifolates (pralatrexate); fusion proteins (denileukin diftitox); nucleoside analogs (pentostatin, gemcitabine); and other agents (e.g.alisertib, plitidepsin, bendamustine, bortezomib).A variety of interesting novel combinations is also emerging.It is hoped that these innovative approaches, coupled with a greater understanding of the clinicopathologic features, pathogenesis, molecular biology, and natural history of PTCL will advance the field and improve outcomes in this challenging group of diseases.This review summarizes the currently available clinical evidence on the various approaches to treating relapsed/refractory PTCL, including the role of stem cell transplantation, with an emphasis on potential new drug therapies.